NEW YORK, Feb. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative inhaler device designs - is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalation (DPI) as a formidable challenger to more established pulmonary methods such as metered dose inhalers and nebulizers. The importance of inhalation devices in drug delivery has traditionally derived from their ability to deliver pharmaceuticals to the upper lung and respiratory system for localized treatment of pulmonary diseases such as asthma and emphysema. While this remains the most attractive near-term market for DPI, the systemic delivery of both small and large molecule biologics and engineered macromolecules for the treatment of a range of pathologies represents significant long-term potential for dry powder pulmonary delivery systems.
To order this report:: Dry Powder Inhalation